Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.16 -2.5%	$1.22	$0.86 ▼ $3.78	$257.38M	0.35	4.41 million shs	4.73 million shs
CUE Cue Biopharma	$0.82 -0.9%	$0.77	$0.45 ▼ $1.99	$62.88M	1.53	257,113 shs	353,957 shs
SCPH scPharmaceuticals	$5.52 +13.8%	$4.59	$1.94 ▼ $6.28	$294.21M	0.4	485,318 shs	17.53 million shs
TKNO Alpha Teknova	$4.48 -5.7%	$4.82	$4.00 ▼ $10.37	$239.73M	0.32	363,305 shs	135,455 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+8.18%	-20.67%	+12.26%	-54.41%
CUE Cue Biopharma	0.00%	0.00%	-6.44%	+24.89%	+7.34%
SCPH scPharmaceuticals	0.00%	+5.43%	-13.39%	+46.53%	-9.68%
TKNO Alpha Teknova	0.00%	+1.28%	-8.30%	-20.44%	-4.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.6204 of 5 stars	3.4	3.0	0.0	1.6	2.5	0.6
CUE Cue Biopharma	2.9478 of 5 stars	0.0	5.0	4.7	3.9	0.8	0.6
SCPH scPharmaceuticals	4.5245 of 5 stars	3.3	5.0	4.2	3.2	1.7	0.6
TKNO Alpha Teknova	1.6521 of 5 stars	3.8	1.0	0.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	627.97% Upside
CUE Cue Biopharma	0.00	N/A	N/A	N/A
SCPH scPharmaceuticals	2.67	Moderate Buy	$14.00	153.62% Upside
TKNO Alpha Teknova	3.50	Strong Buy	$10.00	123.21% Upside

Current Analyst Ratings Breakdown

Latest CUE, TKNO, SCPH, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	SCPH scPharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/22/2025	TKNO Alpha Teknova	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	12,869.04	N/A	N/A	$2.01 per share	0.58
CUE Cue Biopharma	$8.29M	7.59	N/A	N/A	$0.28 per share	2.92
SCPH scPharmaceuticals	$49.97M	5.89	N/A	N/A	$0.27 per share	20.44
TKNO Alpha Teknova	$37.74M	6.35	N/A	N/A	$1.55 per share	2.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.11	N/A	N/A	N/A	N/A	-55.99%	-42.75%	11/6/2025 (Estimated)
CUE Cue Biopharma	-$40.67M	-$0.56	N/A	N/A	N/A	-469.35%	-230.13%	-111.16%	11/13/2025 (Estimated)
SCPH scPharmaceuticals	-$85.15M	-$1.81	N/A	N/A	N/A	-183.55%	-1,647.86%	-71.76%	11/12/2025 (Estimated)
TKNO Alpha Teknova	-$26.75M	-$0.42	N/A	N/A	N/A	-55.24%	-26.51%	-18.40%	11/6/2025 (Estimated)

Latest CUE, TKNO, SCPH, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/12/2025	Q2 2025	CUE Cue Biopharma	-$0.13	-$0.09	+$0.04	-$0.09	$2.00 million	$2.95 million
8/7/2025	Q2 2025	SCPH scPharmaceuticals	-$0.30	-$0.34	-$0.04	-$0.34	$15.41 million	$16.04 million
8/7/2025	Q2 2025	TKNO Alpha Teknova	-$0.1004	-$0.07	+$0.0304	-$0.07	$9.90 million	$10.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	8.92	8.92
CUE Cue Biopharma	0.01	1.60	1.60
SCPH scPharmaceuticals	3.86	3.85	3.14
TKNO Alpha Teknova	0.17	5.87	4.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CUE Cue Biopharma	35.04%
SCPH scPharmaceuticals	89.52%
TKNO Alpha Teknova	13.81%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CUE Cue Biopharma	10.78%
SCPH scPharmaceuticals	4.78%
TKNO Alpha Teknova	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	221.88 million	192.59 million	Optionable
CUE Cue Biopharma	60	76.85 million	67.43 million	Optionable
SCPH scPharmaceuticals	30	53.30 million	50.75 million	Optionable
TKNO Alpha Teknova	240	53.51 million	46.83 million	Not Optionable

CUE, TKNO, SCPH, and ALLO Headlines

Recent News About These Companies

Alpha Teknova (NASDAQ:TKNO) Announces Earnings Results

August 11, 2025 | marketbeat.com

Alpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

Alpha Teknova (TKNO) Q2 Revenue Jumps 7%

August 8, 2025 | aol.comA

CenterBook Partners LP Takes Position in Alpha Teknova, Inc. (NASDAQ:TKNO)

August 8, 2025 | marketbeat.com

Teknova Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

July 24, 2025 | globenewswire.com

Pleasing Signs As A Number Of Insiders Buy Alpha Teknova Stock

July 9, 2025 | finance.yahoo.com

Martha J. Demski Sells 8,000 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) Stock

July 2, 2025 | insidertrades.com

Alpha Teknova, Inc. (TKNO) Income Statement - Yahoo Finance

June 28, 2025 | ca.finance.yahoo.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Teknova Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Alpha Teknova (TKNO) Traded Lower on Increased Uncertainty

April 30, 2025 | msn.com

Alpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025

April 24, 2025 | quiverquant.comQ

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | globenewswire.com

Alpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation system

March 20, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | globenewswire.com

Teknova, Pluristyx announce collaboration over next-generation cell therapies

March 11, 2025 | markets.businessinsider.com

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

March 11, 2025 | globenewswire.com

Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67

March 8, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, TKNO, SCPH, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.16 -0.03 (-2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$1.19 +0.03 (+2.59%)

As of 06:22 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Cue Biopharma NASDAQ:CUE

$0.82 -0.01 (-0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 0.00 (-0.27%)

As of 04:10 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

scPharmaceuticals NASDAQ:SCPH

$5.52 +0.67 (+13.81%)

Closing price 04:00 PM Eastern

Extended Trading

$5.48 -0.04 (-0.72%)

As of 06:59 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Alpha Teknova NASDAQ:TKNO

$4.48 -0.27 (-5.68%)

Closing price 04:00 PM Eastern

Extended Trading

$4.48 0.00 (0.00%)

As of 04:10 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time